Arsenic is a naturally occurring element widely distributed in the earth’s crust. In the environment, arsenic is combined with oxygen, chlorine, and sulfur to form inorganic arsenic compounds. Arsenic in animals and plants combines with carbon and hydrogen to form organic arsenic compounds.
Breathing high levels of inorganic arsenic can give you a sore throat or irritated lungs.
Ingesting very high levels of arsenic can result in death. Exposure to lower levels can cause nausea and vomiting, decreased production of red and white blood cells, abnormal heart rhythm, damage to blood vessels, and a sensation of “pins and needles” in hands and feet.
Ingesting or breathing low levels of inorganic arsenic for a long time can cause a darkening of the skin and the appearance of small “corns” or “warts” on the palms, soles, and torso.
Children raised in homes using indoor coal for cooking or heating appear to be about a half-inch shorter at age 36 months than those in households using other fuel sources, according to a report posted online today that will appear in the June print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
ZIOPHARM Oncology, today announced the pricing of an underwritten public offering of 9,600,000 shares of its common stock at a price to the public of $5.75 per share.
Pregnant women eating baked clay could be exposing themselves and their unborn child to toxic chemicals, according to research by De Montfort University (DMU) in Leicester, UK.
A Kansas State University scientist is digging deep to solidify information about potential tungsten contamination in the nation's groundwater and aquifers.
ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).
DSM BioSolutions, Royal DSM's microbial fermentation contract manufacturing business, and BiAqua B.V., an innovator in delivering bio-based solutions for serious water contamination issues, today announced that they have entered into an agreement for strain development, process development and production of "BiAqua Ferritin" for BiAqua's core technology to address bio-fouling and arsenic contamination in the water sector.
ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.
ZIOPHARM Oncology, Inc., announced today that the first patient has been dosed in a Phase I, single arm, dose escalation study at the Indiana University Cancer Center of intravenous (IV) palifosfamide (ZIO-201) in combination with etoposide (VP-16) and cisplatin/carboplatin (platinum) in the treatment of small cell lung cancer (SCLC) and other cancers.
Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.
Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia.
Dartmouth recently received a $2 million pilot grant to fund the new Children's Environmental Health and Disease Prevention Center at Dartmouth. The grant is jointly funded by the United States Environmental Protection Agency (EPA) and the National Institute for Environmental Health Sciences (NIEHS). Dartmouth's is one of six emerging centers nationally that are undertaking interdisciplinary research to assist public health professionals and policy makers in combating children's diseases caused by environment pollutants.
ZIOPHARM Oncology, Inc. announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology in Orlando Florida.
The well-reported arsenic contamination of drinking water in Bangladesh called the "largest mass poisoning of a population in history" by the World Health Organization and known to be responsible for a host of slow-developing diseases has now been shown to have an immediate and toxic effect on the struggling nation's economy.
A new study which benchmarks the abilities of laboratories around the world to measure heavy metals (arsenic, cadmium, lead, mercury, methylmercury and inorganic arsenic) in seafood has been published today by the Joint Research Centre.
ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.
Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when administered after standard initial treatment, according to a new, multi-center study led by a researcher at Wake Forest University Baptist Medical Center.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2010, and provided a business update. The Company also announced the filing of a shelf registration statement with the Securities and Exchange Commission to replace its existing shelf registration, which expires in December 2010.
Central and Eastern Europe is facing 'significant challenges' in combating a multi-billion euro, and often lethal, trade in fake medicines, security and pharmaceutical groups have warned, Inter Press Service reports in an article that examines the scope of the problem in a region now identified as a key smuggling route in an illicit trade which is growing every year.
Scientists have solved an important mystery about why an arsenic compound, called arsenite, can kill us, and yet function as an effective therapeutic agent against disease and infections. According to new research published in the October 2010 issue of Genetics scientists from Johns Hopkins, Baylor and Stanford discovered that arsenite, a common water contaminant in many parts of the world, affects a special protein folding machine in yeast, called TCP, also present in humans.
Adeona Pharmaceuticals, Inc., announced completion of 100% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.